Compare CRBP & ONCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRBP | ONCH |
|---|---|---|
| Founded | 2009 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 221.0M |
| IPO Year | 2014 | 2025 |
| Metric | CRBP | ONCH |
|---|---|---|
| Price | $11.31 | $10.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $45.50 | N/A |
| AVG Volume (30 Days) | ★ 516.3K | 125.1K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $116.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $7.12 | $10.13 |
| 52 Week High | $20.56 | $10.63 |
| Indicator | CRBP | ONCH |
|---|---|---|
| Relative Strength Index (RSI) | 66.21 | 60.97 |
| Support Level | $7.62 | $10.27 |
| Resistance Level | $11.64 | $10.36 |
| Average True Range (ATR) | 0.60 | 0.02 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 83.08 | 80.00 |
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
1RT Acquisition Corp is a blank check company.